Actio Biosciences
San Diego
About Actio Biosciences
Actio Biosciences develops genetics-led therapies for rare and common diseases. The company applies human genetic insights and precision medicine approaches to identify drug targets and advance a pipeline including candidates for Charcot-Marie-Tooth disease type 2C (TRPV4 inhibitor ABS-0871) and KCNT1-related epilepsy (ABS-1230). It conducts preclinical and Phase 1 studies to evaluate safety, tolerability, and pharmacokinetics for its lead programs. The company also engages in collaboration, licensing, and clinical trial planning to support development and potential expansion into more common indications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $121.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2025)
- Website: actiobiosciences.com
- Phone: [email protected]
Industries & Categories
Bioinformatics, Biotechnology, Genetics
Social Profiles
Canonical: https://fsome.com/organization/actio-biosciences-49683 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.